什么是Zeposia？
Zeposia是一种处方药，用于治疗成人的复发型多发性硬化症（MS），包括临床隔离的综合征，复发型疾病和活动性继发进行性疾病。
目前尚不清楚这种药物对儿童是否安全有效。

 
Zeposia可能会导致严重的副作用，包括：
1.感染。Zeposia可能会增加严重感染的风险，这种感染可能威胁生命并导致死亡。Zeposia可以减少血液中白细胞（淋巴细胞）的数量。通常在停止治疗后的3个月内恢复正常。您的医疗保健提供者可能会在开始治疗之前对您的白细胞进行血液检查。
如果您在Zeposia治疗期间以及上次服药后3个月内有以下任何感染症状，请立即致电您的医疗保健提供者：
■发热
■感觉很累
■流感样症状
■咳嗽
■排尿疼痛和频繁（尿路感染的迹象）
■皮疹
■头痛伴发烧，颈部僵硬，对光，恶心或意识模糊敏感（这些可能是脑膜炎的症状，大脑和脊柱周围的衬里感染）
如果感染，您的医疗服务提供者可能会延迟启动或停止您的Zeposia治疗。
2.当您开始服用Zeposia时，心率缓慢（也称为缓慢性心律失常）。Zeposia可能会导致您的心律暂时减慢，尤其是在服用Zeposia的前8天内。服用第一剂Zeposia之前，您将需要进行一项检查心电图的检查，称为心电图（ECG）。如果您遇到以下心律缓慢的症状，请致电您的医疗保健提供者：
■头晕
■头昏眼花
■感觉自己的心脏在缓慢地跳动或跳动
■呼吸急促
■混乱
■胸痛
■疲倦



Zeposia最常见的副作用包括：
■上呼吸道感染
■站立时血压低（体位性低血压）
■背痛
■肝酶升高
■排尿频繁且痛苦（尿路感染的迹象）
■高血压
这些并非Zeposia的所有可能的副作用。有关更多信息，请咨询您的医疗保健提供者或药剂师。致电您的医疗保健提供者以获取有关副作用的医疗建议。您可以通过1-800-FDA-1088向FDA报告副作用。
 

谁不应该服用Zeposia？
如果您执行以下操作，请勿服用Zeposia：
1.在过去的6个月中曾患有心脏病，胸痛（不稳定的心绞痛），中风或小中风（短暂性脑缺血发作或TIA）或某些类型的心力衰竭。
2.曾经或曾经有某些类型的不规则或异常心跳（心律不齐）病史，但没有起搏器纠正。
睡眠期间出现未经治疗的严重呼吸问题（睡眠呼吸暂停）。
3.服用某些称为单胺氧化酶（MAO）抑制剂的药物（例如司来吉兰，苯乙嗪，利奈唑胺）。
4.如果您患有以下任何一种情况，或者在不知道是否患有这些任何一种情况，请在服用Zeposia之前与您的医疗服务提供者联系。
5.服用Zeposia之前
服用Zeposia之前，请告知您的医疗保健提供者所有您的医疗状况，包括您是否：
发烧或感染，或者由于某种疾病而无法抵抗感染，或者服用或服用了会降低免疫系统的药物。
在过去30天内已接种疫苗或计划接种疫苗。Zeposia可能会导致疫苗效力降低。
在开始使用Zeposia治疗之前，如果您以前从未接种过水痘疫苗，那么您的医疗服务提供者可能会给您接种水痘疫苗（水痘带状疱疹病毒）。
曾经感染过水痘或已接种水痘疫苗。您的医疗保健提供者可能会对水痘病毒进行血液检查。您可能需要获得完整的水痘疫苗疗程，然后等待1个月才能开始服用Zeposia。
心律缓慢。
心律不齐或异常（心律不齐）。
有中风病史。
有心脏病，包括心脏病发作或胸痛。
有高血压。
有肝脏问题。
有呼吸问题，包括在睡眠期间。
有眼疾，特别是眼炎称为葡萄膜炎。
有糖尿病。
6.正在怀孕或打算怀孕。狂犬病可能会伤害未出生的婴儿。如果您怀孕或计划怀孕，请与您的医疗保健提供者联系。如果您是可能怀孕的女性，则在使用Zeposia治疗期间以及停止服用Zeposia后的3个月内，应使用有效的节育措施。与您的医疗保健提供者讨论这段时间适合您的节育方法。
7.如果您在服用Zeposia期间怀孕或在停止服用Zeposia后三个月内怀孕，请立即告知您的医疗保健提供者。
8.正在母乳喂养或计划母乳喂养。不知道Zeposia是否会进入您的母乳。与您的医疗保健提供者谈谈服用Zeposia的最佳喂养方式。
9.告诉您的医疗保健提供者您已服用或最近服用过的所有药物，包括处方药和非处方药，维生素和草药补品。与其他药物一起使用Zeposia可能会导致严重的副作用。尤其要告诉您的医疗保健提供者您是否服用或服用过：
■影响您免疫系统的药物，例如阿仑单抗
■控制心律（心律不齐）或心跳的药物
■强效CYP2C8抑制剂，如吉非贝齐或氯吡格雷
■抑制乳腺癌抗性蛋白转运蛋白的药物，例如环孢霉素和Eltrombopag
■CYP2C8诱导剂，如利福平
■阿片类药物（止痛药）
■治疗抑郁症的药物
■治疗帕金森氏病的药物
■在使用Zeposia治疗期间，服用Zeposia之前至少1个月以及停止服用Zeposia之后的3个月内，您不应接种活疫苗。在使用Zeposia治疗期间给予疫苗可能效果不佳。
■如果不确定是否服用这些药物，请与您的医疗保健提供者联系。
■知道你吃的药。保留一份清单，以在您购买新药时向您的医疗保健提供者和药剂师显示。
 


我应该如何服用Zeposia？
您将收到7天的入门包。您必须在第一周通过缓慢增加剂量来开始Zeposia。
请遵循下表中的剂量表。这可以降低心律减慢的风险。
1-4天 每天1次服用0.23毫克（浅灰色胶囊）
5-7天 每天1次服用0.46毫克（半浅灰色和橙色的胶囊）
第8天及之后 每天1次服用0.92毫克（橙色胶囊）
完全按照您的医疗保健提供者告诉您的服用Zeposia。
每天服用Zeposia 1次。
整个吞咽Zeposia胶囊。
服用Zeposia食用或不食用。
避免使用某些酪胺含量高（超过150毫克）的食物，例如陈年，发酵，腌制，熏制和腌制的食物。服用Zeposia时吃这些食物可能会增加血压。
在没有与您的医疗服务提供者首先交谈之前，不要停止服用Zeposia。
不要跳过剂量。
使用7天的入门包开始服用Zeposia。
如果在治疗的前14天内错过了Zeposia剂量的1天或更多天，请与您的医疗保健提供者联系。您需要从另一个Zeposia 7天入门包开始。
如果在治疗的前14天错过了Zeposia剂量，请在第二天服用下一个预定的剂量。



我应该如何存放Zeposia？
将Zeposia存放在68°F至77°F（20°C至25°C）之间的室温下。
将Zeposia和所有药品放在儿童接触不到的地方。
有关安全有效使用Zeposia的一般信息。
有时出于药物指南中列出的目的以外的目的开出药物。不要在没有规定的条件下服用Zeposia。即使他人有与您相同的症状，也不要将Zeposia给予他人。可能会伤害他们。您可以询问您的医疗保健提供者或药剂师，以获取有关专为健康专业人员编写的Zeposia的信息。
 

Zeposia中的成分是什么？
有效成分：ozanimod
非活性成分：胶体二氧化硅，交联羧甲基纤维素钠，硬脂酸镁和微晶纤维素。
胶囊壳包含：黑色氧化铁，明胶，红色氧化铁，二氧化钛和黄色氧化铁。

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.1 Zeposia, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based first-dose observation required for patients.1,4,5 An up-titration scheme should be used to reach the maintenance dosage of Zeposia, as a transient decrease in heart rate and atrioventricular conduction delays may occur.1

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves, creating damaging lesions that make it harder for signals to travel between each nerve cell.6,7 This “signal breakdown” can lead to symptoms and relapses.6,8

“With the FDA approval of Zeposia, appropriate patients with relapsing forms of multiple sclerosis will have another oral treatment option with meaningful efficacy to help address the disease’s hallmark relapses and brain lesions,”9 said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. “Zeposia has substantial clinical potential, and we are well positioned with our heritage in transformational science to ensure this innovative compound ultimately benefits as many patients as possible.”

The approval is based on data from the largest pivotal, head-to-head RMS studies with an active comparator to date: the randomized, active-controlled Phase 3 SUNBEAM™ (safety and efficacy of Zeposia versus interferon beta-1a in relapsing multiple sclerosis) and RADIANCE™ (safety and efficacy of the selective sphingosine 1-phosphate receptor modulator Zeposia in relapsing multiple sclerosis) Part B clinical trials of more than 2,600 adults.1,2,3,10 In both trials – as compared to AVONEX® (interferon beta-1a), Zeposia delivered powerful efficacy as measured by annualized relapse rate (ARR), as well as on the number and size of brain lesions.1,2,3

· Zeposia demonstrated a relative reduction in ARR versus AVONEX of 48% through one year and 38% at two years (absolute ARR of 0.18 versus 0.35 and 0.17 versus 0.28, respectively).1,2,3

· At one year, treatment with Zeposia reduced the number of T1-weighted gadolinium-enhanced (GdE) brain lesions more than AVONEX (0.16 vs 0.43), a relative reduction of 63%, and reduced the number of new or enlarging T2 lesions (1.47 vs. 2.84), a relative reduction of 48%.1,3

· At two years, treatment with Zeposia reduced the number of T1-weighted gadolinium-enhanced (GdE) brain lesions more than AVONEX (0.18 vs 0.37), a relative reduction of 53%.1,2 Zeposia also reduced the number of new or enlarging T2 lesions vs AVONEX (1.84 vs 3.18), a relative reduction of 42%.1,2

There was no statistically significant difference in the three-month and six-month confirmed disability progression between Zeposia- and AVONEX- treated patients over two years.1

Zeposia demonstrated acceptable safety and tolerability in the Phase 3 SUNBEAM and RADIANCE Part B trials.1,2,3 Zeposia is contraindicated in patients who in the last six months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure; patients who have a presence of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial, unless the patient has a functioning pacemaker; patients with severe untreated sleep apnea; and patients taking a monoamine oxidase inhibitor.1 Zeposia is associated with the following Warnings and Precautions: increased risk of infections, bradyarrhythmia and atrioventricular conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, posterior reversible encephalopathy syndrome, additive immunosuppressive effects from prior immune-modulating treatments, severe increase in disability after stopping Zeposia, and immune system effects after stopping Zeposia.1 Please see Important Safety Information for additional details. The most common adverse reactions (incidence ≥4%) were upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.1

Before initiation of treatment with Zeposia, all patients require assessments including a recent complete blood count including lymphocyte count (within six months or after discontinuation of prior MS therapy), an ECG to determine whether preexisting conduction abnormalities are present, a recent liver function test (within six months), and consideration of current and prior medications, including vaccinations.1 For patients with a history of uveitis or macular edema, an ophthalmic assessment is required.1

“Treatment for relapsing forms of multiple sclerosis is critical to address this devastating neurological disease.11 I’m excited, with the introduction of Zeposia, I will have a new oral option to offer my RMS patients that has demonstrated efficacy and safety,”1 said Bruce Cree, M.D., Ph.D., M.A.S., professor of clinical neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center.

“Multiple sclerosis is an unpredictable and often disabling disease that affects nearly one million people in the United States.9,12 Ongoing treatment with disease-modifying therapy can reduce the number of disease attacks,”11 said Bruce Bebo, executive vice president of research, National Multiple Sclerosis Society. “Each person can respond differently to these medications, which is why having treatment options is so important. We are pleased that there will now be another effective treatment option for people with MS.”

As the country’s healthcare system is dealing with the unprecedented COVID-19 pandemic, Bristol Myers Squibb has made the decision to delay commercialization of Zeposia. The Company made the decision based on what’s in the best health interest of our patients, customers and employees. Bristol Myers Squibb will continue to monitor the environment and will partner with the neurology community to inform launch timing.

A Marketing Authorization Application for Zeposia for the treatment of adults with relapsing-remitting multiple sclerosis in the European Union is currently under review with the European Medicines Agency (EMA). A regulatory decision from the EMA is expected in the first half of 2020.

About SUNBEAM™

SUNBEAM is a pivotal, phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of oral Zeposia (0.92 mg, equivalent to 1 mg) against weekly intramuscular AVONEX® (interferon beta-1a) for at least a 12-month treatment period.3 The study included 1,346 people living with RMS across 152 sites in 20 countries.3

The primary endpoint of the trial was annualized relapse rates (ARR) during the treatment period.3 The secondary MRI endpoints included the number of new or enlarging hyperintense T2-weighted brain MRI lesions over 12 months and number of gadolinium-enhanced brain MRI lesions at month 12.3

An analysis of the time to onset of three-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase 3 trials.1,2,3

About RADIANCE™

RADIANCE Part B is a pivotal, phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of oral Zeposia (0.92 mg, equivalent to 1 mg) against weekly intramuscular AVONEX® (interferon beta-1a) over a 24-month treatment period.2 The study included 1,320 people living with RMS across 150 sites in 21 countries.2

The primary endpoint of the trial was ARR over 24 months.2 The secondary MRI endpoints included the number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months.2

An analysis of the time to onset of three-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase 3 trials.1,2,3

About Multiple Sclerosis

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves.6 The myelin damage disrupts communication between the brain and the rest of the body.7 Ultimately, the nerves themselves may deteriorate — a process that's currently irreversible.13

RMS, including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, is characterized by clearly defined attacks of worsening neurologic function.14 These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease.14 RMS is the most common disease course at the time of diagnosis.14 Approximately 85% of patients are initially diagnosed with RMS, compared with 10-15% with progressive forms of the disease.14

About Zeposia (ozanimod)

Zeposia® is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.1 Zeposia blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood1 The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown but may involve the reduction of lymphocyte migration into the central nervous system.1

Zeposia is also in development for additional immune-inflammatory indications, including ulcerative colitis and Crohn's disease.15,16

Indication

Zeposia is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

Contraindications:

· Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial, unless the patient has a functioning pacemaker

· Patients with severe untreated sleep apnea

· Patients taking a monoamine oxidase (MAO) inhibitor

Infections: Zeposia may increase the susceptibility to infections. Life-threatening and rare fatal infections have occurred in patients receiving Zeposia. Obtain a recent (i.e., within 6 months or after discontinuation of prior MS therapy) complete blood count (CBC) including lymphocyte count before initiation of Zeposia. Delay initiation of Zeposia in patients with an active infection until the infection is resolved. Consider interruption of treatment with Zeposia if a patient develops a serious infection. Continue monitoring for infections up to 3 months after discontinuing Zeposia

· Herpes zoster was reported as an adverse reaction in Zeposia-treated patients. Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating Zeposia. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with Zeposia

· Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another S1P receptor modulator. If CM is suspected, Zeposia should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.

· Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability. No cases of PML were identified in active-controlled MS clinical trials with Zeposia. PML has been reported in patients treated with S1P receptor modulators and other MS therapies and has been associated with some risk factors. If PML is suspected, withhold Zeposia and perform an appropriate diagnostic evaluation. If confirmed, treatment with Zeposia should be discontinued

· In clinical studies, patients who received Zeposia were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS. Concomitant use of Zeposia with any of these therapies would be expected to increase the risk of immunosuppression. When switching to Zeposia from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects

· Use of live attenuated vaccines should be avoided during and for 3 months after treatment with Zeposia. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of Zeposia

Bradyarrhythmia and Atrioventricular Conduction Delays: Since initiation of Zeposia may result in a transient decrease in heart rate and atrioventricular conduction delays, dose titration is recommended to help reduce cardiac effects. Initiation of Zeposia without dose escalation may result in greater decreases in heart rate. If treatment with Zeposia is considered, advice from a cardiologist should be sought for those individuals:

· with significant QT prolongation

· with arrhythmias requiring treatment with Class 1a or III anti-arrhythmic drugs

· with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, and uncontrolled hypertension

· with a history of Mobitz type II second-degree or higher AV block, sick-sinus syndrome, or sinoatrial heart block

Liver Injury: Elevations of aminotransferases may occur in patients receiving Zeposia. Obtain liver function tests, if not recently available (i.e., within 6 months), before initiation of Zeposia. Patients who develop symptoms suggestive of hepatic dysfunction should have hepatic enzymes checked and Zeposia should be discontinued if significant liver injury is confirmed. Caution should be exercised when using Zeposia in patients with history of significant liver disease

Fetal Risk: There are no adequate and well-controlled studies in pregnant women. Based on animal studies, Zeposia may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 3 months after stopping Zeposia

Increased Blood Pressure: Increase in systolic pressure was observed after about 3 months of treatment and persisted throughout treatment. Blood pressure should be monitored during treatment and managed appropriately. Certain foods that may contain very high amounts of tyramine could cause severe hypertension in patients taking Zeposia. Patients should be advised to avoid foods containing a very large amount of tyramine while taking Zeposia

Respiratory Effects: Zeposia may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy, if clinically indicated

Macular edema: S1P modulators have been associated with an increased risk of macular edema. Patients with a history of uveitis or diabetes mellitus are at increased risk. Patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation and regular follow-up examinations. An ophthalmic evaluation is recommended in all patients at any time if there is a change in vision. Continued use of Zeposia in patients with macular edema has not been evaluated; potential benefits and risks for the individual patient should be considered if deciding whether Zeposia should be discontinued

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported in patients receiving a S1P receptor modulator. If a Zeposia-treated patient develops unexpected neurological or psychiatric symptoms or any symptom/sign suggestive of an increase in intracranial pressure, a complete physical and neurological examination should be conducted. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, treatment with Zeposia should be discontinued

Unintended Additive Immunosuppressive Effects From Prior Immunosuppressive or Immune-Modulating Drugs: When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation. Initiating treatment with Zeposia after treatment with alemtuzumab is not recommended

Severe Increase in Disability After Stopping Zeposia: Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping Zeposia treatment so patients should be monitored upon discontinuation

Immune System Effects After Stopping Zeposia: After discontinuing Zeposia, the median time for lymphocyte counts to return to the normal range was 30 days with approximately 90% of patients in the normal range within 3 months. Use of immunosuppressants within this period may lead to an additive effect on the immune system, therefore caution should be applied when initiating other drugs 4 weeks after the last dose of Zeposia

Most common Adverse Reactions (≥ 4%): upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

For additional safety information, please see the full Prescribing Information and Medication Guide.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, whether Zeposia (ozanimod) for the indication described in this release will be commercially successful and that continued approval of Zeposia for such indication described in this release may be contingent upon verification and description of clinical benefit in confirmatory trials. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol-Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

1. 1 Zeposia (ozanimod) capsules for oral use. Bristol Myers Squibb Pharmaceutical Corporation. Full prescribing information. 3/2020.
2 Cohen, JA, Comi, G, Selmaj, KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016/S1474-4422(19)30238-8.
3 Comi, G, Kappos, L, Selmaj, KW, et at. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomized, minimum 12-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016/S1474-4422(19)30239-X.
4 GILENYA (fingolimod) capsules for oral use. Novartis Pharmaceuticals Corporation. Full prescribing information. 8/2019.
5 MAYZENT (siponimod) tablets for oral use. Novartis Pharmaceuticals Corporation. Full prescribing information. 3/2019.
6 National Multiple Sclerosis Society. Definition of MS. www.nationalmssociety.org/What-is-MS/Definition-of-MS. Accessed on March 25, 2020.
7 National Multiple Sclerosis Society. What is Myelin? www.nationalmssociety.org/What-is-MS/Definition-of-MS/Myelin. Accessed March 25, 2020.
8 National Multiple Sclerosis Society. MS Symptoms. www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed March 25, 2020.
9 National Multiple Sclerosis Society. MS The Disease. www.nationalmssociety.org/About-the-Society/Press-Room/MS-the-Disease. Accessed on March 25, 2020.
10 McCann Agency. Pivotal Trials for MS Therapies: Zeposia –2 head-to-head with Active Comparator Based on PIs. March 2020.
11 National Multiple Sclerosis Society. Treating RMSS. www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS/Treatment. Accessed on March 25, 2020.
12 National Multiple Sclerosis Society. How Many People Live with MS? www.nationalmssociety.org/What-is-MS/How-Many-People. Accessed March 25, 2020.
13 National Multiple Sclerosis Society. What Causes MS? www.nationalmssociety.org/What-is-MS/What-Causes-MS. Accessed March 25, 2020.
14 National Multiple Sclerosis Society. Types of MS. www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed March 25, 2020.
15 Celgene. A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease. Available from www.clinicaltrials.gov/ct2/show/NCT03467958. NLM identifier: NCT03467958.
16 Celgene. To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis. Available from www.clinicaltrials.gov/ct2/show/NCT03915769. NLM identifier: NCT03915769.

Source: Bristol-Myers Squibb Company

Posted: March 2020